Grifols, S.A. (NASDAQ:GRFS) Receives $10.00 Average Target Price from Analysts

Grifols, S.A. (NASDAQ:GRFS) has been assigned a consensus recommendation of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $10.00.

Several analysts have recently issued reports on GRFS shares. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Zacks Research cut Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th. Finally, JPMorgan Chase & Co. decreased their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th.

Grifols Trading Up 1.1%

Shares of GRFS opened at $9.02 on Thursday. The stock has a market capitalization of $6.20 billion, a PE ratio of 47.47, a P/E/G ratio of 0.37 and a beta of 0.67. The company’s fifty day moving average is $8.99 and its 200 day moving average is $9.46. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.93 and a current ratio of 2.48. Grifols has a fifty-two week low of $6.19 and a fifty-two week high of $11.14.

Hedge Funds Weigh In On Grifols

A number of large investors have recently made changes to their positions in GRFS. Brandes Investment Partners LP boosted its position in Grifols by 8.9% in the 2nd quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock valued at $253,441,000 after buying an additional 2,294,113 shares during the period. Vinva Investment Management Ltd purchased a new position in shares of Grifols during the second quarter worth approximately $256,000. Norges Bank bought a new stake in shares of Grifols during the second quarter valued at approximately $17,538,000. Vestmark Advisory Solutions Inc. purchased a new stake in shares of Grifols in the second quarter valued at approximately $414,000. Finally, State of Wyoming bought a new position in Grifols in the second quarter worth approximately $1,729,000.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.